MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "MAO-B inhibitors"

  • 2018 International Congress

    Safinamide in Parkinson’s disease

    G. Martí-Andrés, R. Jiménez-Bolaños, J. Arbelo-González, J. Pagonabarraga-Mora, C. Duran-Herrera, M. Carmona-Abellán, R. Luquin-Puido (Pamplona, Spain)

    Objective: To evaluate clinical effects, safety and tolerability of safinamide add-on levodopa in Parkinson’s disease (PD) patients. Background: Safinamide is a recently approved adjunctive treatment…
  • 2018 International Congress

    Efficacy and safety of Rasagiline in treatment of gait disturbances in dementia with Lewy bodies

    A. Chimagomedova, O. Levin, M. Anikina, I. Ayzenberg (Moscow, Russian Federation)

    Objective: We aimed to investigate the efficacy and safety of rasagiline in addition to levodopa in patients with dementia with Lewy bodies (DLB). Background: Management…
  • 2018 International Congress

    Safinamide add-on therapy increases ON time without dyskinesia in fluctuating Parkinson’s Disease (PD) patients with moderate to severe dyskinesia

    V. Tubazio, C. Cattaneo, E. Bonizzoni, C. Keywood (Bresso (Milan), Italy)

    Objective: This post-hoc analysis examined safinamide efficacy for providing dyskinesia-free ON time in LID patients. Background: Safinamide has both dopaminergic and glutamate modulating activity. The…
  • 2018 International Congress

    Evaluation of the interaction between safinamide and opicapone in Parkinson’s disease patients with fluctuations

    J. Garcia-Caldentey, MA. Prats-Sedano, I. Legarda-Ramirez, E. Estelrich-Peyret, B. Vives-Pastor, PJ. Garcia (Palma de Mallorca, Spain)

    Objective: To describe and to evaluate a Balearic ongoing Parkinson's disease (PD) Project to evaluate the efficacy and tolerance of the interaction between safinamide and…
  • 2018 International Congress

    Safinamide effect in patients with Parkinson’s disease and deep brain stimulation

    F. Mancini, A. Di Fonzo, G. Lazzeri, L. Borellini, V. Silano, M. Lacerenza, C. Comi (Milan, Italy)

    Objective: Aim of this retrospective study is to evaluate safety and efficacy of safinamide in the treatment of motor complications in patients with Parkinson’s Disease…
  • 2018 International Congress

    Use of safinamide: A clinical practice review of 2 year experience

    C. Borrue-Fernandez (San Sebastian Reyes, Spain)

    Objective: Review the clinical use, efectivity and side efects in a population based cohort. Background: Safinamide is an oral, once a day adjunctive therapy for…
  • 2018 International Congress

    Anti-glutamatergic effect of safinamide in Parkinson’s Disease: A TMS study

    A. Guerra, A. Suppa, V. D'Onofrio, F. Di Stasio, F. Asci, G. Fabbrini, A. Berardelli (Rome, Italy)

    Objective: To test the effect of safinamide, at the doses of 50 and 100 mg/day, on primary motor cortex (M1) excitability and glutamatergic neurotransmission in…
  • 2017 International Congress

    The SYNAPSES study  (StudY to observe SafiNAmide in clinical Practice during the firSt post-commErcialization phaSe): methodology and results from the European feasibility survey

    G. Camattari, G. Abbruzzese, W. Jost, J. Kulisevsky, V. Tubazio, L. Simoni, The SYNAPSES investigators (Bresso, Italy)

    Objective: Here we present the design of a Drug Utilization Study of safinamide in the first post-commercialization phase and report results of the study feasibility…
  • 2017 International Congress

    Safinamide improves both motor and non-motor symptoms in fluctuating Parkinson’s Disease patients.

    C. Cattaneo (Bresso (Milan), Italy)

    Objective: To investigate the efficacy of safinamide, compared to placebo, as add-on therapy to stable doses of levodopa, on both motor and non-motor symptoms in…
  • 2016 International Congress

    Long-term efficacy of safinamide on mood in Parkinsonian patients with fluctuations

    C. Cattaneo, E. Mueller, M. Sardina (Bresso, Italy)

    Objective: The present post-hoc analysis of the results of two pivotal trials (016 and 018) investigated the effects of safinamide 100 mg/day on mood in…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley